Cellectis S.A. American Depositary Shares (CLLS) trades on Nasdaq and is classified in the Technology sector. Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications. This page tracks CLLS using verified market data, the company's most recently reported financial statements, its earnings record and Ticker-Terminal's analytical models. Every figure is shown with its source and the time it was last verified, and values we cannot verify are labelled rather than filled in.
Previous close
$1.10
Volume
99,075
52-week range
$1.09 – $5.48
Market cap
$110.8M
Source: Polygon (snapshot) · Verified Oct 14, 2026, 3:59 PM EDT
1D
+1.82%
1W
-16.42%
1M
-38.80%
1Y
-73.14%
Percentage change calculated from verified closing prices. Periods without full provider coverage are marked unavailable rather than estimated.
Revenue (TTM)
Revenue growth (YoY)
EPS (TTM, diluted)
EPS growth (YoY)
Gross margin
Operating margin
Net margin
Operating cash flow (TTM)
Revenue 2-year CAGR
P/E (trailing)
P/E (forward, est.)
Market cap
Polygon / Finnhub reference
Dividend yield
Ticker-Terminal does not publish a dividend yield for this ticker until a verified distribution is on file.
Next earnings date
Not yet scheduled by the company
Latest reported quarter
Awaiting first reported quarter
Diluted EPS 0.01
| Period | EPS actual | Estimate | Surprise |
|---|---|---|---|
| 2026-06-30 | -0.22 | -0.28 | +20.9% |
| 2026-03-31 | -0.18 | -0.28 | +36.0% |
| 2025-12-31 | -0.26 | -0.26 | +1.8% |
| 2025-09-30 | 0.01 | -0.29 | +103.5% |
Analysis temporarily unavailable because required market data could not be verified.
Analysis temporarily unavailable because required market data could not be verified.
Rating
Buy
Average target
Unavailable
Range
Unavailable
Analysts
13
Source: finnhub
Some data is delayed, stale or unavailable. Everything shown is still verified.
Company profile and business overview · Earnings history
This page is the free public summary. Inside Ticker-Terminal you get quarterly forecasts, EPS estimate tracking, earnings deep dives, fair-value modelling and AI research built on the same verified provider data and filings.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Cellectis S.A. American Depositary Shares trades under the ticker CLLS on Nasdaq.
CLLS was last verified at $1.12 (1.82% on the day). After hours, last verified Oct 14, 2026, 3:59 PM EDT. Market data may be delayed and is shown with its own timestamp.
Create a free Ticker-Terminal account to run a full AI research report on CLLS — earnings breakdown, quarterly forecasts, bull, base and bear cases, and fair value ranges built on verified provider data and filings.
Free guide series
Two emails. The 7-step checklist now, then the next guide in the series — starting with Which AI is best for stock research.
Market data on this page is supplied by third-party providers, may be delayed, and is shown with the time it was last verified. Financial figures come from CLLS's most recently reported statements and are not restated by Ticker-Terminal.
Scores, fair-value ranges and bull, base and bear scenarios are analytical models calculated from verified data. They are educational information, not investment advice, not a price prediction, and not a recommendation to buy or sell any security. Past performance does not indicate future results.
See our risk disclosure. Page data assembled Oct 14, 2026, 6:27 PM EDT.